Clinical and Molecular Hepatology

Papers
(The H4-Index of Clinical and Molecular Hepatology is 36. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Preface387
Unveiling etiology-specific blood biomarkers in hepatocellular carcinoma: A gateway to personalized medicine: Editorial on “Multiomics profiling of buffy coat and plasma unveils etiology-specific sign313
Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future230
Approaches to quantifying hepatitis B virus covalently closed circular DNA198
Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answer193
Baveno VI-SSM was able to stratify the risk of portal hypertension-related events in patients with HBV-related cirrhosis159
Correspondence to editorial on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis”107
Comment: Non-invasive prediction of post-sustained virological response hepatocellular carcinoma in hepatitis C virus105
Downregulation of the MARC1 p.A165 risk allele reduces hepatocyte lipid content by increasing beta-oxidation85
From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials76
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity73
Comparison of four histological scoring systems for autoimmune hepatitis to improve diagnostic sensitivity73
Nonalcoholic fatty liver disease-based risk prediction of adverse pregnancy outcomes: Ready for prime time?70
Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)70
Anti-fibrotic treatments for chronic liver diseases: The present and the future69
U-shaped relationship between urea level and hepatic decompensation in chronic liver diseases62
Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort study60
Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial58
Comprehensive analysis of transcriptomic biomarkers for predicting response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma56
Reply to authors’ reply: “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis”53
Equivalent prevalence and progression of chronic kidney disease in non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease50
Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–202349
Correspondence to editorial on “Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study”49
Radiogenomics of intrahepatic cholangiocarcinoma predicts immunochemotherapy response and identifies therapeutic target49
Reconsidering treatment indications for chronic hepatitis B: Insights from the TORCH-B roll-over study: Editorial on “Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A49
The role of SPP1 in MASLD pathogenesis: Therapeutic insights into ursolic acid’s mechanisms of action: Correspondence to editorial on “Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 c46
Leaky gut-derived tumor necrosis factor-α causes sarcopenia in patients with liver cirrhosis45
Toward hepatitis C virus elimination using artificial intelligence44
Liver organoids: Current advances and future applications for hepatology43
Carbon Ion Radiotherapy in the Treatment of Hepatocellular Carcinoma42
Current evidence and the potential role of proton beam therapy for hepatocellular carcinoma42
Hepatocytes infected with hepatitis C virus change immunological features in the liver microenvironment40
Treatment response to nucleos(t)ide analogs in chronic hepatitis B with mildly elevated alanine aminotransferase: Letter to the editor on “Antiviral therapy for chronic hepatitis B with mildly elevate39
Personalized approaches to the treatment of hepatocellular carcinoma using immune checkpoint inhibitors: Editorial on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunothe39
Deep learning-based prediction of molecular cancer biomarkers from tissue slides: A new tool for precision oncology37
A decade of liver organoids: Advances in disease modeling37
Predicting decompensation risk in compensated HBV cirrhosis: Eternal sunshine for a spotless mind?36
0.080816030502319